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Health technology assessments (HTAs) rely on comparative evidence about new 
treatments and competing therapies, which are typically derived using indirect or 
mixed treatment comparisons (ITC/MTCs). These are not always feasible or appro-
priate, particularly in rapidly evolving therapeutic areas, like oncology. For instance, 
some comparisons may not be possible due to incomplete evidence networks; or, 
heterogeneity between studies due to differences in design or population may 
make an MTC inappropriate. There is, therefore, a need for alternative techniques, 
such as Simulated Treatment Comparisons (STCs). This technique is designed to 
derive comparisons between treatments after adjustment for differences between 
the populations of the two studies. This targeted comparison requires individual 
patient-level data (IPD) for at least one of the treatments (the index), and are appro-
priate when the trials used for the comparison are sufficiently comparable in design 
and methods, but differ in the profiles of their population in measured risk factors. 
The differences can be adjusted analytically using IPD via regression equations. This 
produces endpoint estimates for the index treatment that reflect the profile of the 
comparator population. These can then be contrasted with published results for 
the comparator to obtain a measure of difference between treatments. Since only 
measured risk factors can be included in the adjustment, the potential for residual 
confounding remains. Another potential bias is a possible “study effect” whereby 
other differences between studies distort the comparisons. This can be assessed 
using the reference groups of the trials, if these received the same treatment. STCs 
have been used in HTA submissions, and it is likely that its use and that of other 
alternative techniques will increase particularly in areas with rapid drug develop-
ment. In the presence of heterogeneity or incomplete evidence networks, STCs can 
provide comparative evidence where these may be otherwise deemed unavailable 
due to limitations of ITCs/MTCs.
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RCTs remain the gold standard for evaluation of drug efficacy and safety. However, 
the only way of identifying treatment pathways and improving understanding of 
costs and outcomes at different stages of care is via longitudinal observational 
studies. Observational data from electronic health records (EHRs) are increas-
ingly being used to support pharmaco-epidemiological research. Coverage, data 
quality and validity of UK EHR databases such as the Clinical Practice Research 
Datalink (CPRD) have improved in recent years, and many papers confirm the 
validity of data in diagnoses such as cancer. Published data show that recording 
of cancer diagnosis and mortality in primary care electronic records is generally 
consistent with Cancer Registry (CR) data in England. The use of “read codes” in 
CPRD to identify an event (cancer diagnosis or referral to secondary care) and 
the possibility of anonymous linkage to secondary care databases (e.g. Hospital 
Episode Statistics [HES] for information about hospital management as an in- or 
out-patient, to other CR data, and accurate mortality tracking by the Office for 
National Statistics [ONS]) allows the data and diagnosis to be validated against 
multiple sources, as well as identifying treatment pathways in both secondary 
and primary care. There are some limitations, e.g. not all patients identified in GP 
practices via the CPRD are linked to other databases. Management data such as 
secondary care prescribing are difficult to access (not available in HES) but may 
be available from reviewing anonymized patient notes or by connecting to other 
datasets. For example, IMS Health links CPRD data with hospital pharmacy audit 
data and HES data. However these data have only become available recently, are 
expensive to access and currently patient population coverage is low. We will 
provide a detailed description of the possibilities for integrated database use to 
map treatment pathways for cancer patients.
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Single technology appraisals (STAs) are a key component of the development of 
NICE technology appraisals guidance, but are a time and resource intensive process. 
Societal costs are incurred during STAs by holding the NICE Appraisal Committee, 
via payment to the evidence review group (ERG) and in the opportunity costs of 
other technologies which are not appraised. In addition, the drug manufacturer 
also incurs substantial costs in preparation of their submission and throughout 
the STA process. Recently aripiprazole, an atypical antipsychotic drug for the treat-
ment of manic episodes in adolescent bipolar I disorder, was subjected to an STA 
and received positive guidance. It was apparent to the ERG from the outset of the 
appraisal that the conclusion would be positive as: the drug had a small acquisi-
tion cost; was already in widespread use; would shortly be going generic; and had 
a profile similar to its comparators. As the budget impact over a 5-year period esti-
mated by the manufacturer was less than the payment received by the ERG, it was 
unlikely that the STA represented efficient use of resources. Given a fundamental 
role of NICE is in assessing cost-effectiveness, the option of un-referring STAs in 
rare circumstances has appeal. It is proposed that if certain criteria are met then 
it would be more cost-effective to not proceed with an STA. These include: small 
patient population, commonly used in current clinical practice, patent expiring in 
Systematic reviews aim to identify, select, synthesize and appraise all high qual-
ity research evidence relevant to a particular research question, and are widely 
accepted as the gold standard for providing the best evidence for use in decision 
making. They are essential, routine components of submission data packages 
for health technology assessments (HTAs) of products undergoing evaluation 
for reimbursement and market access. Additionally, systematic reviews are 
often the source for clinical evidence used in health economic modelling to 
evaluate cost-effectiveness. Thus, they represent a substantial investment of 
resources, and incorrect or incomplete reviews could invalidate the proposed 
clinical and economic value of a product set out in a health technology submis-
sion and result in unfavourable reimbursement decisions and/or delayed market 
access. There are a number of best practice criteria set down for systematic 
reviews; the most widely recognised being from the Cochrane group. However, 
when carrying out a systematic review for HTA purposes researchers should 
be aware of the additional requirements set out by each agency. The Cochrane, 
UK National Institute for Clinical Excellence (NICE) and Germany’s Institut für 
Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWIG) methodologi-
cal guidelines for conducting and reporting systematic reviews were analysed 
and an ‘inclusive’ checklist of requirements was developed to ensure the sys-
tematic review and meta-analysis met the broad set of HTA requirements and 
minimise the risk of having to repeat the procedure or create the need for a 
HTA review group to carry out its own review, which could potentially lead to 
an unfavourable reimbursement decision or a restriction on use. An aware-
ness of specific HTA systematic review requirements can help optimise the 
preparation of a data package for HTA submission and hence maximise the 
chances of success.
PRM225
Can a Multi-CRiteRia deCiSion (MCd) oPtiMiSation Model helP 
deCiSion MakeRS in the oPtiMal SeleCtion oF vaCCineS When 
exPanding theiR univeRSal MaSS vaCCination PRogRaMMe? the  
CaSe oF Poland
Topachevskyi O.1, Standaert B.1, Van Bellinghen L.A.2, Van Vlaenderen I.2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2CHESS, Ternat, Belgium
Objectives: The model aims to determine the optimal allocation of financial 
resources amongst various paediatric vaccines accounting for changes in budget 
and availability of new vaccines over time. This approach aims to inform decision 
makers who are seeking to extend their national immunisation programmes 
about the optimal mix of vaccines and sequence of their introduction, meanwhile 
accounting for their preferences in clinical and cost outcomes. MethOds: An 
MCD optimisation model was developed in Microsoft Excel that considered avail-
ability of new vaccines and budget changes over time, optimal mix of vaccines 
in previous years, budget investment time horizon, cumulative outcomes time 
horizon, maximal achievable vaccination coverage, specific target populations. 
The optimal mix of vaccines within an available portfolio was determined by 
manually programmed linear optimisation based on a defined objective func-
tion and budget constraints. The objective function includes maximisation of 
prevention of disease cases, GP visits, hospitalisations, deaths, and cost sav-
ings in disease management. A multi-criteria approach allows for redistributing 
weights across clinical and cost outcomes in the objective function. Vaccination 
against rotavirus, varicella, influenza and pneumococcal disease was evaluated, 
based on disease incidences and direct medical costs from Poland. Relative risk 
reductions induced by vaccination were based on randomised controlled trials 
and post-marketing surveillance data. Results: Dependent on the definition of 
objective function, the allocation of budget across a portfolio of vaccines resulted 
in different recommendations. If deaths-avoided was weighted at maximum, 
pneumococcal vaccine was ranked first, followed by rotavirus and influenza vac-
cination. If cost savings received the maximum preference, vaccination against 
influenza was ranked first, rotavirus second, pneumococcal third, and varicella 
fourth. The use of a weighted objective function resulted in different vaccines 
introduction sequences. cOnclusiOns: The use of an MCD optimisation model 
provides a tool to inform decision makers about the optimal allocation of finan-
cial resources over time.
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With the rapid pervasion of internet technologies, demand for making health 
economic evidence, such as mathematical models, accessible through the web 
increases. Long running computations such as Monte Carlo simulation can impair 
user experience because of longer waiting time. Our aim is to employ mathematical 
techniques to reduce the computation time of probabilistic cost effectiveness Monte 
Carlo models, thus increasing their acceptance when used on the web. We employ 
the variance reduction technique to reduce computation time while obtaining out-
comes with the same Monte Carlo error. The control variate approach is applied. 
It utilizes information about errors in estimates of known mean Net Monetary 
Benefit (NMB) quantities to reduce errors in estimation of the cost-effectiveness 
acceptability curve. The NMB mean value is calculated based on the deterministic 
counterpart of the model. The said technique has been applied to the published 
probabilistic decision tree-based Excel model for evaluating cost-effectiveness of 
breast cancer screening. In this model, different types of probability distributions 
can be chosen to model uncertainty of disease incidence, mortality rate and inter-
vention effectiveness. By applying the control variate approach we were able to 
achieve outcome with the same error while performing 50% less simulations as 
compared to the plain Monte Carlo method. Such performance improvement is yet 
another step towards increasing user acceptance of web based health economic 
models with Monte Carlo simulations.
